

A phase 2 study of the PI3K δ inhibitor piasalisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Tracking no: ADV-2023-010648R2

Tyler Phillips (University of Michigan, United States) Abraham Avigdor (Sackler Faculty of Medicine, Tel Aviv University, Israel) Ronit Gurion (Institute of Hematology, Rabin Medical Center & Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Israel) Caterina Patti (University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Italy) Paolo Corradini (University of Milan, Italy) Monica Tani (Ospedale di Ravenna, Azienda Unità Sanitaria Locale della Romagna, Spain) Amitkumar Mehta (UAB, United States) Izidore Lossos (University of Miami, United States) Pier Zinzani (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Italy) Catherine Thieblemont (AP-HP, Hôpital Saint-Louis, Hemato-oncologie, DMU DHI, F-75010 Paris, France, France) Wojciech Jurczak (Maria Skłodowska-Curie National Research Institute of Oncology, Poland) Fred Zheng (Incyte Corporation, Wilmington, DE, USA, United States) Erica Rappold (Incyte Corporation, Wilmington, DE, USA, United States) Wanying Zhao (Incyte Corporation, Wilmington, DE, USA, United States) Ping Jiang (School of Cancer Sciences, University of Southampton, UK, United Kingdom) Peter Johnson (University of Southampton, United Kingdom)

Abstract:

Piasalisib, a potent and highly selective PI3K δ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell lymphomas. The phase 2 CITADEL-204 study (NCT03144674, EudraCT 2017-000970-12) assessed efficacy and safety of piasalisib in BTK inhibitor-experienced (cohort 1) or BTK inhibitor-naïve (cohort 2) patients with R/R marginal zone lymphoma (MZL). Patients aged ≥ 18 years with histologically confirmed R/R MZL, treated with ≥ 1 prior systemic therapy (including ≥ 1 anti-CD20 antibody) received piasalisib 20 mg once daily (QD) for 8 weeks then 20 mg once weekly (weekly dosing group [WG]) or piasalisib 20 mg QD for 8 weeks then 2.5 mg QD (daily dosing group [DG]); DG was selected for further assessment. Primary endpoint of the study was objective response rate (ORR). Owing to slower than expected recruitment, cohort 1 was closed with 10 patients (WG: n = 4; DG: n = 6) enrolled. Based on a planned interim analysis in cohort 2, the futility boundary was not crossed and enrollment continued to study completion. At data cut-off (Jan 15, 2021), 100 patients were enrolled and treated in cohort 2 (WG: n = 28; DG: n = 72). In the DG, the ORR (95% confidence interval [CI]) was 58.3% (46.1-69.8), with a complete response rate (95% CI) of 4.2% (0.9-11.7); the lower bound of the ORR 95% CI exceeded the protocol defined threshold of 40%. The median (95% CI) duration of response was 12.2 months (8.1-17.5) and progression-free survival was 16.5 months (11.5-20.6); median overall survival was not reached. The most common treatment-emergent adverse events (TEAEs) among all patients were diarrhea (47.0%), cough (23.0%), and rash (18.0%); the most common grade ≥ 3 TEAEs included diarrhea (12.0%), neutropenia, and pneumonia (9.0% each). TEAEs led to dose interruptions, reductions, and discontinuations in 56.0%, 16.0%, and 29.0% of all patients, respectively. Durable responses and overall manageable safety profile were demonstrated in patients with R/R MZL treated with piasalisib monotherapy.

Conflict of interest: COI declared - see note

COI notes: Conflict-of-interest disclosure: T.J.P. reports consultancy: AbbVie, Bayer, Beigene, Bristol Myers Squibb, Cardinal Health, Incyte Corporation, Karyopharm, and Seattle Genetics; travel, accommodations, or expenses: Incyte Corporation; and research funding: AstraZeneca and Pharmacyclics. A.A. reports consultancy: Gilead Sciences, Pfizer, and Takeda; honoraria: Janssen; and research funding: Bristol Myers Squibb. R.G. reports consultancy: Gilead Sciences, Medison, Novartis, and Takeda; and honoraria: JC Health CARE and Roche. P.C. reports consultancy: AbbVie, Amgen, Celgene, Daiichi Sankyo, F. Hoffman-La Roche Ltd, Gilead Sciences, Incyte Corporation, Janssen, Kyowa Kirin, Kite, Novartis, Sanofi, Servier, and Takeda; honoraria: AbbVie, Amgen, Celgene, Daiichi Sankyo, F. Hoffman-La Roche Ltd, Gilead Sciences, Janssen, Kyowa Kirin, Kite, Novartis, Sanofi, Servier, and Takeda; other: travel, accommodations, expenses (paid by any for-profit health care company): AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead Sciences, Novartis, and Takeda. A.M. reports consultancy: AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead, Incyte Corporation, Kyowa Kirin, MorphoSys/Incyte Corporation, Novartis, Pharmacyclics, Seattle Genetics, and TG Therapeutics; research funding: Affimed, Celgene/Bristol Myers Squibb, Forty Seven Inc./Gilead, I-MAB, Incyte Corporation, Innate Pharmaceuticals, Juno Pharmaceuticals/Bristol Myers Squibb, Kite/Gilead, Merck, Roche-Genentech, Seattle Genetics, Takeda, and TG Therapeutics; speakers' bureau: AstraZeneca, Bristol Myers Squibb, Gilead, Kyowa Kirin, Incyte Corporation, MorphoSys/Incyte, Pharmacyclics, Seattle Genetics, and BeiGene. I.S.L. reports consultancy: Janssen Scientific, Seattle Genetics, and Verastem Oncology; honoraria: Janssen Biotech and Verastem Oncology; other: travel, accommodations, expenses (paid by any for-profit health care company): Janssen and Seattle Genetics; patents and royalties: Stanford University; research funding: NCI. P.L.Z. reports consultancy: Bristol Myers Squibb, Celgene, Celltrion, EUSA Pharma, Gilead Sciences, Immune Design, Janssen, MSD, Portola, Roche, Sandoz, Sanofi, and Verastem Oncology; honoraria: AbbVie, ADC Therapeutics, Bristol Myers Squibb, EUSA Pharma, Gilead Sciences, Incyte Corporation, Janssen, Kyowa Kirin, Merck, Roche, Takeda, TG Therapeutics, and Verastem Oncology; membership on an entity's Board of Directors or advisory committees: AbbVie, ADC Therapeutics, Bristol Myers Squibb, Celgene, Celltrion, EUSA Pharma, Gilead Sciences, Immune Design, Incyte Corporation, Janssen, Kyowa Kirin, Merck, MSD, Portola, Roche, Sandoz, Sanofi, Takeda, and Verastem Oncology; research funding: Portola; speakers' bureau: AbbVie, ADC Therapeutics, Bristol Myers Squibb, Celgene, Celltrion, EUSA Pharma, Gilead Sciences, Immune Design, Incyte Corporation, Janssen, Kyowa Kirin, Merck, MSD, Portola, Roche, Sandoz, Takeda, TG Therapeutics, and Verastem Oncology. C.T. reports consultancy: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Collectis, Kite Pharma/Gilead Sciences, Novartis, and Roche; honoraria: AbbVie, Amgen, Bayer, Celgene, Collectis, Incyte Corporation, Kite Pharma/Gilead Sciences, Novartis, and Roche; membership on an entity's Board of Directors or advisory committees: AbbVie, Amgen, Celgene, Collectis, Kite Pharma/Gilead Sciences, Novartis, and Roche; other: travel, accommodations, expenses (paid by any for-profit health care company): AbbVie, Amgen, Bristol Myers Squibb, Celgene, Collectis Kite Pharma/Gilead Sciences, Novartis, and Roche; research funding: Hospira and Roche; and speakers' bureau: Collectis. W.J. reports consultancy: Acerta, AstraZeneca, BeiGene, Epizyme, European Medicines Agency, Janssen China R&D, and Sandoz-Novartis; research funding: Acerta, Affimed, Bayer, BeiGene, Celgene, Gilead Sciences, MEI Pharma, Nordic Nanovector, Janssen China R&D, Merck, MorphoSys, Pharmacyclics, Roche, Servier, Takeda, and TG Therapeutics; and former employment: Jagiellonian University, Kraków, Poland. F.Z. reports employment and stock ownership: Incyte Corporation. E.R. reports employment and stock ownership: Incyte Corporation. W.Z. reports former employment and stock ownership: Incyte Corporation. P.J. reports former employment and stock ownership: Incyte Corporation. P.J. reports consultancy: Epizyme, Janssen, MorphoSys, OncoImmune Inc, and Takeda; honoraria: Bristol Myers Squibb, Celgene, Genmab, Incyte Corporation, Kite Pharma, Kymera, Novartis, and OncoImmune Inc; and research funding: Epizyme. C.P. and M.T. report no relevant financial relationships to disclose.

Preprint server: No;

Author contributions and disclosures: All authors contributed to the acquisition, analysis, and interpretation of data, as well as to the drafting and critical review of the manuscript, and provided approval of the final version to be published. TJP, PJ (Johnson), FZ, ER, WZ, and PJ (Jiang) directly accessed and verified the underlying data reported in the manuscript.

Non-author contributions and disclosures: Yes; Medical writing assistance was provided by Rachel Shparberg, PhD (Envision Pharma Group, Philadelphia, PA, USA), and funded by Incyte Corporation.

Agreement to Share Publication-Related Data and Data Sharing Statement: Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte Corporation for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase 1 studies) for which the product and indication have been approved on or after Jan 1, 2020 in at least one major market (eg, United States, European Union, and Japan). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte Corporation's clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at:
<https://www.incyte.com/Portals/0/Assets/Compliance%20and%20Transparency/clinical-trialdata-sharing.pdf?ver=2020-05-21-132838-960>.

Clinical trial registration information (if any): NCT03144674, EudraCT 2017-000970-12

A phase 2 study of the PI3K δ inhibitor piasclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Tyrel J Phillips,^{1} Abraham Avigdor,^{2,3} Ronit Gurion,⁴ Caterina Patti,⁵ Paolo Corradini,⁶ Monica Tani,⁷ Amitkumar Mehta,⁸ Izidore S Lossos,⁹ Pier Luigi Zinzani,^{10,11} Catherine Thieblemont,¹² Wojciech Jurczak,¹³ Fred Zheng,¹⁴ Erica Rappold,¹⁴ Wanying Zhao,¹⁴ Ping Jiang,¹⁴ and Peter Johnson¹⁵*

AFFILIATIONS

¹Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA

²Institute of Hematology, Sheba Medical Center, Ramat Gan, Israel

³Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

⁴Institute of Hematology, Rabin Medical Center & Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

⁵Department of Hematology I, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy

⁶University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

⁷Ospedale di Ravenna, Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy

⁸University of Alabama School of Medicine, Birmingham, AL, USA

⁹Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

¹⁰IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy

¹¹Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy

¹²Université de Paris; APHP, Hôpital Saint-Louis, Hémato-oncologie, Paris Diderot, Paris, France

¹³Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland

¹⁴Incyte Corporation, Wilmington, DE, USA

¹⁵School of Cancer Sciences, University of Southampton, UK

*Current affiliation: City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Running title: Parsaclisib monotherapy in patients with R/R MZL

SUPPORT

This study was sponsored by Incyte Corporation (Wilmington, DE, USA).

CORRESPONDING AUTHOR

Tyrel J Phillips, MD

City of Hope Comprehensive Cancer Center

1500 E Duarte Road, Duarte, CA 91010 USA

Email: tphillips@coh.org; Telephone: +1 626-725-1208

Data sharing statement

Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte Corporation for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase 1 studies) for which the product and indication have been approved on or after Jan 1, 2020 in at least one major market (eg, United States, European Union, and Japan). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte Corporation's clinical trial data sharing policy

and instructions for submitting clinical trial data requests are available at:

<https://www.incyte.com/Portals/0/Assets/Compliance%20and%20Transparency/clinical-trialdata-sharing.pdf?ver=2020-05-21-132838-960>

PREVIOUS PUBLICATIONS

Phillips T, et al. Phase 2 study evaluating the efficacy and safety of piasclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204). *Blood* 2020; 136 (suppl 1): 27–28 (Presented at the 62nd ASH Annual Meeting and Exposition, December 5–8, 2020, virtual meeting).

Phillips T, et al. Efficacy and safety of piasclisib in patients with relapsed or refractory marginal zone lymphoma: primary analysis from a phase 2 study (CITADEL-204). *Blood* 2021; 138 (suppl 1): 44 (Presented at the 63rd ASH Annual Meeting and Exposition, Dec 11–14, Atlanta, GA, USA).

Type of paper: Original Article

Abstract

Parsaclisib, a potent and highly selective PI3K δ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell lymphomas. The phase 2 CITADEL-204 study (NCT03144674, EudraCT 2017-000970-12) assessed efficacy and safety of parsaclisib in BTK inhibitor-experienced (cohort 1) or BTK inhibitor-naive (cohort 2) patients with R/R marginal zone lymphoma (MZL). Patients aged ≥ 18 years with histologically confirmed R/R MZL, treated with ≥ 1 prior systemic therapy (including ≥ 1 anti-CD20 antibody) received parsaclisib 20 mg once daily (QD) for 8 weeks then 20 mg once weekly (weekly dosing group [WG]) or parsaclisib 20 mg QD for 8 weeks then 2.5 mg QD (daily dosing group [DG]); DG was selected for further assessment. Primary endpoint of the study was objective response rate (ORR). Owing to slower than expected recruitment, cohort 1 was closed with 10 patients (WG: n = 4; DG: n = 6) enrolled. Based on a planned interim analysis in cohort 2, the futility boundary was not crossed and enrollment continued to study completion. At data cut-off (Jan 15, 2021), 100 patients were enrolled and treated in cohort 2 (WG: n = 28; DG: n = 72). In the DG, the ORR (95% confidence interval [CI]) was 58.3% (46.1–69.8), with a complete response rate (95% CI) of 4.2% (0.9–11.7); the lower bound of the ORR 95% CI exceeded the protocol defined threshold of 40%. The median (95% CI) duration of response was 12.2 months (8.1–17.5) and progression-free survival was 16.5 months (11.5–20.6); median overall survival was not reached. The most common treatment-emergent adverse events (TEAEs) among all patients were diarrhea (47.0%), cough (23.0%), and rash (18.0%); the most common grade ≥ 3 TEAEs included diarrhea (12.0%), neutropenia, and pneumonia (9.0% each). TEAEs led to dose interruptions, reductions, and discontinuations in 56.0%, 16.0%, and 29.0% of all patients, respectively. Durable responses and

overall manageable safety profile were demonstrated in patients with R/R MZL treated with
parsaclisib monotherapy.

Key Points

- Parsaclisib, a highly selective, potent PI3K δ inhibitor, demonstrated durable responses and an overall manageable safety in R/R MZL
- Investigation is needed to determine patients who may benefit from PI3K pathway inhibition as an alternative to $\geq 2L$ standard-care agents

Introduction

Marginal zone lymphoma (MZL), an indolent non-Hodgkin lymphoma (NHL), accounts for 5–15% of all NHLs in Western countries.^{1,2} Treatment options for symptomatic patients include rituximab with or without chemotherapy³; however, patients tend to experience serial relapses and require multiple lines of therapy.⁴ Second- and subsequent-line options for patients with relapsed or refractory (R/R) MZL include lenalidomide in combination with anti-CD20 therapies,^{3,5,6} and zanubrutinib (Bruton tyrosine kinase [BTK] inhibitor) following at least one prior anti-CD20-based therapy^{7,8} (accelerated approval of another BTK inhibitor ibrutinib was recently withdrawn by the sponsor for this indication).⁹

In B-cell malignancies, upregulation of the phosphatidylinositol-3 kinase (PI3K) pathway, particularly the PI3K δ isoform, is a critical driver of tumor growth and survival.^{10,11} PI3K inhibitors have demonstrated clinically meaningful efficacy in the treatment of various R/R NHLs, with reported objective response rates (ORRs) of 39–87% in MZL.¹²⁻¹⁵ However, challenges surrounding safety and tolerability from on-target and off-target effects related to the selectivity and potency of current therapies restrict the ability to optimize efficacy outcomes.¹¹

Parsaclisib is a potent, highly selective, next-generation PI3K δ inhibitor designed to improve tolerability while maintaining strong inhibition.¹⁶ Parsaclisib inhibited PI3K δ activity (half-maximal concentration = 1 nM) and was at least 10,000-fold more selective for PI3K δ compared with PI3K α , PI3K β , and PI3K γ in biochemical assays.^{16,17} In the phase 1/2 CITADEL-101 study (NCT02018861),¹⁸ parsaclisib demonstrated differentiated tolerability, with near absence of grade ≥ 2 transaminitis, and encouraging clinical outcomes in patients with R/R NHL including MZL. Here, we report primary results from the CITADEL-204 study conducted to further evaluate the efficacy and safety of parsaclisib in patients with R/R MZL.

Methods

Trial oversight

CITADEL-204 was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and applicable local regulations. The protocol and all amendments were reviewed and approved by Institutional Review Boards or Independent Ethics Committees before study initiation, and written informed consent was obtained from each patient before study enrollment.

Study design

This phase 2, multicenter, open-label study evaluated efficacy and safety of piasclisib in patients with R/R MZL, with (cohort 1) or without (cohort 2) prior treatment with the BTK inhibitor ibrutinib (the only BTK inhibitor approved when the study was designed and initiated; Supplemental Figure 1). This report focuses on cohort 2; owing to slower than expected recruitment, cohort 1 was closed early.

The first 60 patients enrolled in cohort 2 and all patients in cohort 1 were assigned originally in a 1:1 ratio into either the weekly dosing group (WG) or the daily dosing group (DG); before opening of the expansion cohort, it was decided to enroll all patients into the DG based on collective preliminary data across the CITADEL-203, -204, and -205 trials. At the end of the enrollment in cohort 2, only 28 patients were enrolled in the WG and 72 in the DG. Patients in the WG received oral piasclisib 20 mg once daily (QD) for 8 weeks followed by 20 mg once weekly (QW); patients in the DG received oral piasclisib 20 mg QD for 8 weeks followed by 2.5 mg QD. After the initial 20-mg QD dosing, the subsequent lower dosing of 20

mg QW or 2.5 mg QD was proposed to maintain response while reducing the intensity and frequency of adverse events (AEs). An additional 30 patients in cohort 2 were planned for enrollment for better understanding of safety and efficacy. All patients were required to receive a standard *Pneumocystis jirovecii* pneumonia (PJP) prophylaxis regimen while receiving parsaclisib and for 2–6 months after the last dose of parsaclisib. Cytomegalovirus infection was monitored by polymerase chain reaction.

After an initial evaluation of safety and efficacy from this study and other monotherapy studies in NHL, the DG was selected as the study treatment regimen; all patients were enrolled in the DG thereafter. Patients in the WG could cross over to the DG or remain on their current regimen. Treatment for all patients continued until disease progression, death, unacceptable toxicity, or consent withdrawal.

Patients

Key inclusion criteria included patients at least 18 years of age with histologically confirmed R/R MZL (extranodal, nodal, and splenic subtypes); prior treatment with at least one systemic therapy including at least one anti-CD20 antibody; radiographically measurable (computed tomography [CT] or magnetic resonance imaging [MRI]) lymphadenopathy or extranodal lymphoid malignancy (defined as having at least one lesion that measures >1.5 cm in the longest transverse diameter and \geq 1.0 cm in the longest perpendicular diameter; patients with splenic MZL who did not meet radiographically measurable disease criteria were eligible if bone marrow infiltration was histologically confirmed); willingness to undergo an incisional or excisional lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most

recent available archival tissue; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2, and adequate hematologic, hepatic, and renal function.

Key exclusion criteria were known histologic transformation from indolent NHL to diffuse large B-cell lymphoma; history of primary or secondary central nervous system lymphoma; prior treatment with PI3K inhibitors; receiving allogeneic or autologous stem cell transplantation, immunosuppressive therapy, anticancer, potent CYP34A inducers/inhibitors, or investigational drugs within protocol-defined intervals before the study; active graft versus host disease; history of stroke or intracranial hemorrhage within 6 months of the study; chronic or active infection requiring treatment (including human immunodeficiency virus, hepatitis B virus, and hepatitis C virus); or exposure to a live vaccine within 30 days of dosing.

Study endpoints and assessments

The primary endpoint was independent review committee (IRC)–determined ORR assessed by CT or MRI according to Lugano classification response criteria for lymphomas.¹⁹ Secondary endpoints included complete response (CR) rate, best percentage change in disease burden (measured as the best percentage change in the sum of product of diameters of all target lesion sizes for patients with measurable disease at baseline, or the best percentage change in the enlarged portion of the spleen for patients with splenomegaly only at baseline), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety and tolerability. Measurable disease by CT or MRI and bone marrow examinations were performed at screening to determine disease status and followed until disease progression. If bone marrow disease was present at baseline, a bone marrow biopsy was required to confirm CR.

Safety was assessed by monitoring AE frequency, duration, and severity (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03), as well as physical examinations, vital signs, 12-lead electrocardiogram, ECOG PS, and clinical laboratory blood and urine samples. The AEs of special interest including colitis, diarrhea, exfoliative dermatitis, febrile neutropenia, rash, intestinal perforation, pneumonitis, pneumonia and PJP, cytomegalovirus, herpes simplex virus, and varicella zoster virus infections were monitored. Laboratory events of special interest included decreased neutrophils, increased alanine transferase (ALT), and increased aspartate aminotransferase (AST). Colonoscopies with biopsies were recommended but not mandated as part of the evaluation of an event such as colitis, and no formal data were collected.

Exploratory endpoints included profiles of blood biomarkers at baseline and on-treatment associated with response, resistance, and safety of parsaclisib. Whole blood was collected for pharmacokinetic analysis and translational biomarker analysis of serum proteins (ie, changes in protein analytes associated with B-cell lymphoma and immune cell function). Study assessments were performed at protocol-defined time points (Supplemental Table 1), and serum samples were analyzed for relative expression levels of approximately 1000 proteins by proximity extension assays (Olink Proteomics, Boston, MA, USA).

Statistical analyses

A sample size of approximately 90 patients was selected so that if the true ORR is 60% for patients in both treatment groups, there would be approximately 96% probability of observing the lower bound of the 95% confidence interval (CI) of ORR \geq 40%. An interim futility analysis was planned once 30 patients in cohort 2 were treated and evaluated for response or had

permanently discontinued study treatment owing to disease progression, withdrawal of consent, or death. The study was to be terminated if the futility boundary was crossed (≤ 10 of the 30 patients responded [ie, CR or PR] based on IRC assessment).

The full analysis set (used for summary of demographics, baseline characteristics, patient disposition, and all efficacy analyses) and the safety population (used for all safety analyses) consisted of patients who received at least one dose of parsaclisib. The pharmacokinetic/pharmacodynamic-evaluable population included patients who received at least one dose of parsaclisib and provided at least one post-dose plasma sample.

No statistical comparisons were planned for this study. Patients initially assigned to the WG who switched to the DG before starting the 20-mg QW period were included in the DG for analyses, and those who switched after starting the 20-mg QW period were included in the WG for analyses. Unless otherwise stated, all efficacy data presented were determined by the IRC.

Results

Patient demographics and disposition

Between Dec 18, 2017 and Jan 15, 2021 primary analysis data cut-off date, 100 patients were enrolled in cohort 2 at 44 international study sites and treated with parsaclisib (28 patients in the WG; 72 patients in the DG). Three patients switched from weekly to daily dosing after starting the 20-mg QW period. In the total population, median age was 71.0 (range, 35–95), 53.0% were male, and 83.0% were White. At baseline, 95% of patients had an ECOG PS score of 0 to 1 and 82.0% had advanced disease (Ann Arbor Stage III–IV); 31%, 34%, and 35% of patients had nodal, extranodal, and splenic MZL subtypes, respectively. The median number of prior therapies was 2 (range, 1–8), and 49.0% of patients had lymphoma refractory to their most recent

prior therapy (Table 1). Ten patients (4 in the WG; 6 in the DG) had been enrolled in cohort 1 of the study before it was closed; baseline characteristics of these patients are presented in Supplemental Table 2. Results reported hereon are primarily for cohort 2 and the DG unless otherwise specified, and data for cohort 1 are presented in supplement data.

In the DG, 50 patients (69.4%) discontinued treatment and 22 patients (30.6%) remained on treatment at the primary analysis cut-off; the main reasons for treatment discontinuation were AEs (37.5%) and progressive disease (25.0%) (Supplemental Table 3). The median duration of parsaclisib treatment in the DG was 11.6 months (range, 0.4–30.9), and median follow-up time was 21.0 months (range, 11.9–37.0) from the first dose to data cut-off date (Supplemental Table 3). Data for the WG and overall population are presented in Supplemental Table 3.

Efficacy

In an interim analysis of the first 30 treated patients in cohort 2, the ORR was 46.7% (95% CI, 28.3–65.7) and all 14 responders were PR. The futility boundary (≤ 10 of the 30 patients responded) was not crossed and enrollment continued until 100 patients were treated. The efficacy data presented below refer to the DG in cohort 2. At the data cut-off for primary analysis, the ORR based on IRC assessment was 58.3% (95% CI, 46.1–69.8), exceeding the protocol defined ORR 95% CI lower bound of 40%. The CR rate was 4.2% (95% CI, 0.9–11.7) and stable disease (SD) was observed in 30.6% of patients (Table 2). The ORR was 56.5% in extranodal, 48.0% in nodal, and 70.8% in splenic MZL subgroups. In a subgroup analysis of ORR based on patient baseline characteristics, response rates were generally consistent with the primary analysis in the total population and for the DG (Supplemental Figure 2).

Among all 81 evaluable patients in cohort 2 with baseline and at least one valid post-baseline disease assessment (target lesion for patients with measurable disease at baseline or spleen for patients with splenomegaly only at baseline), all patients had tumor regression and among them 82.7% (67 of 81) achieved a >50% reduction in disease burden from baseline (Figure 1). In the DG, the median time to response among 42 responders was 8.1 weeks, with 66.7% of responders demonstrating an objective response at the first 8-week assessment (Figure 2). The median DOR was 12.2 months (95% CI, 8.1–17.5), median PFS was 16.5 months (95% CI, 11.5–20.6) (Figure 2), and estimated 6- and 12-month PFS rates were 86.5% (95% CI, 74.7–93.0) and 63.6% (95% CI, 49.3–74.9) in the DG, respectively. The median OS was not reached in the DG (nor in the total population or the WG) (Figure 2); the estimated 6- and 12-month OS rates were 97.2% (95% CI, 89.2–99.3) and 89.7% (95% CI, 79.7–95.0), respectively. For the WG data, see Supplemental Figure 3.

Among the 10 patients with prior ibrutinib treatment enrolled in cohort 1, ORR by IRC was 40.0% (95% CI, 12.2–73.8) with 4 partial responses (PRs) (Supplemental Table 4) in the total population. The observed DOR for the 4 responders ranged from 1.9 to 8.8 months and observed PFS for all 10 patients ranged from <1 to 10.6 months. Best percentage change from baseline in target lesion size for patients treated in cohort 1 is presented in Supplemental Figure 4.

Safety

The safety population in cohort 2 included all patients who received at least one dose of piasclisib (N = 100). Data from the overall population and the DG are presented in the text and Table 3; data from the WG are provided in Table 3 only. Treatment-emergent adverse events

(TEAEs) occurred in 96 patients (96.0%) overall and in 70 patients (97.2%) in the DG (Table 3). The most common TEAEs were diarrhea (overall 47.0%; DG 52.8%), cough (overall 23.0%; DG 26.4%), and rash (overall 18.0%; DG 18.1%). Among patients who experienced any-grade diarrhea, the median time to onset was 2.7 (range, 0.03–23.85) and 2.6 (range, 0.03–23.85) months overall and in the DG, respectively; the median (95% CI) time to resolution of any grade diarrhea was 1.6 (1.0–2.6) and 1.5 (0.9–2.6) months overall and in the DG, respectively, and the median (95% CI) time to improvement to grade ≤ 2 from grade ≥ 3 diarrhea was 0.4 (0.1–0.8) months both overall and in the DG. TEAEs led to parsaclisib discontinuation in 29 (29.0%) and 27 (37.5%) patients overall and in the DG, respectively; the most common TEAEs leading to parsaclisib discontinuation were diarrhea (overall 9.0%; DG 12.5%) and colitis (overall 5.0%; DG 6.9%). Treatment interruptions due to TEAEs were required by 56 (56.0%) and 43 (59.7%) and dose reductions by 16 (16.0%) and 12 (16.7%) patients overall and in the DG, respectively. Treatment-related AEs were reported in 83 (83.0%) and 60 (83.3%) patients overall and in the DG group, respectively. The most common treatment-related AEs were diarrhea (overall 42.0%; DG 48.6%) and pruritus (overall 11.0%; DG 11.1%). Treatment-related hematological events included neutropenia (overall 10.0%; DG 9.7%), anemia (overall 7.0%; DG 8.3%), eosinophilia (overall 3.0%; DG 2.8%) and thrombocytopenia (overall 3.0%; DG 1.4%).

Grade ≥ 3 TEAEs occurred in 63 patients (63.0%) in the total population and in 52 patients (72.2%) in the DG in cohort 2. Grade ≥ 3 TEAEs occurring in $\geq 5\%$ patients of the total population were diarrhea (overall 12.0%; DG 15.3%), neutropenia (overall 9.0%; DG 11.1%), pneumonia (overall 9.0%; DG 9.7%), colitis (overall 7.0%; DG 9.7%), anemia (overall 6.0%; DG 8.3%), and febrile neutropenia (overall 5.0%; DG 5.6%). Serious TEAEs occurred in 47 patients (47.0%) in the total population and 40 patients (55.6%) in the DG; serious TEAEs

occurring in $\geq 5\%$ of patients in the total population were pneumonia (overall 9.0%; DG 9.7%), colitis (overall 6.0%; DG 8.3%), and febrile neutropenia (overall 5.0%; DG 5.6%). Six patients experienced fatal TEAEs during the study; worsened general condition (in the WG), and COVID-19 pneumonia, *Enterobacter* sepsis, febrile neutropenia, mental status change, and sepsis (each in the DG).

For AEs of special interest, in addition to diarrhea, colitis, rash, and pneumonia (presented above), febrile neutropenia occurred in 5 patients (5.0%; 4 patients in the DG), cytomegalovirus infection and pneumonitis in 2 patients each (2.0%; both in the DG), and herpes simplex virus infection in 1 patient (1.0%; DG) (Table 4; data for the WG is presented in Table 4). No AEs of PJP were reported as of data cut-off.

Select new or worsening hematologic and chemistry laboratory abnormalities are presented in Supplemental Table 5. The most common new or worsening hematology laboratory parameters for the total population included decreases in neutrophils (53.0%), hemoglobin (32.0%), and platelets (20.0%). Any-grade or grade 3/4 increases in ALT occurred among 27.0% and 5.0% of patients, respectively, and AST occurred among 22.0% and 3.0% of patients, respectively.

Nine of the 10 patients (90%) in cohort 1 had at least one TEAE (Supplemental Table 6), and 6 (60%) had TEAEs that were considered related to parsaclisib by the investigator. Grade ≥ 3 TEAEs occurred in 6 patients (60%) and serious TEAEs in 4 patients (40%). One patient experienced a fatal TEAE (sepsis); no TEAEs were reported as leading to discontinuation of parsaclisib in cohort 1.

Biomarker analysis

Baseline and on-treatment serum samples were available for 75 patients for exploratory translational analyses. Serum proteomic analysis from samples at week 4 demonstrated that piasaalisib reduced the expression of several cytokines, chemokines, and transmembrane receptors from baseline to week 4, including CXCL13/BCA1, FCER2, IL10, LTA/TNFB, TNFRSF4, TNFRSF9, and TNFRSF13B (see Supplemental Table 7 for all significantly [$P < .05$] changed proteins and Supplemental Figure 5 for representative CXCL13 and TNFRSF9 results).

Discussion

Approved treatment options for patients with R/R MZL in the United States include anti-CD20 plus lenalidomide⁵ and therapy targeting the BTK pathway (zanubrutinib).⁷ Patients with R/R MZL who do not respond to or who experience excessive toxicity on approved treatments have few alternatives, underscoring the need for new therapies. Piasaalisib, a potent and highly selective PI3K δ inhibitor, was investigated in this phase 2 study to evaluate efficacy and safety in patients with R/R MZL. In the overall population in cohort 2, treatment with piasaalisib achieved an IRC-assessed ORR of 58.0%, and a >50% reduction in disease burden from baseline (ie, best percentage change in target lesions for patients with measurable target lesions at baseline or enlarged spleen for patients with only splenomegaly as measurable disease at baseline, as defined in Study endpoints and assessment above) was observed in 82.7% of patients. In the DG, the IRC-assessed ORR was 58.3%, including 3 patients with a CR, 39 patients with a PR, and 22 patients who achieved SD. Although the CR rate was relatively low (4.2%), piasaalisib produced a rapid and durable response, with a median time to onset of

response of 8.1 weeks and a clinically relevant DOR of 12.2 months. Treatment with piasclisib also demonstrated efficacy in WG, with an ORR of 57.1% and observed DOR range of 1.9 to 8.8 months among responders. The overall efficacy findings from this study are consistent with those observed in the phase 1 CITADEL-101 study in patients with NHL,¹⁸ and the CITADEL-203 study in R/R follicular lymphoma (FL).²⁰

Several AEs associated with PI3K inhibition appear to be a class effect; inhibitors of the δ isoform (such as idelalisib,²¹ umbralisib¹⁴ and zandelisib²²) are associated with AEs including transaminitis, diarrhea, colitis, pneumonitis, neutropenia, and rash. Inhibition of the ubiquitously expressed α isoform (such as with copanlisib, a dual α and δ inhibitor¹³) is associated with AEs including hyperglycemia and hypertension, whereas infections and autoimmune toxicities have been observed upon inhibition of δ and γ isoforms (such as with duvelisib¹²). Consistent with the known safety profile of PI3K δ inhibitors, no novel safety events were reported with piasclisib monotherapy in either weekly or daily treatment regimens; more events were reported with continuous dosing and observed toxicities were likely attributable to on-target PI3K δ -associated effects.¹¹ TEAEs were experienced by 96.0% of patients overall, with the most common being diarrhea, cough, and rash. Diarrhea occurred more frequently and had a shorter time to onset (2.6 vs 3.6 months) in patients from the DG compared with the WG; discontinuation of treatment due to toxicity was also more common in the DG (37.5% vs 7.1%). Although AEs were managed by dose reductions in 56-60% or interruptions in 16-17% of patients, TEAEs led to piasclisib discontinuation in 29-37.5% of patients. Most patients treated with piasclisib maintained normal ALT and AST values throughout the study, likely owing to the high selectivity and structural design of piasclisib to reduce PI3K δ inhibitor-associated hepatotoxicity.^{16,17} No clinically meaningful trends were observed on health-related quality-of-life outcomes, assessed

using Functional Assessment of Cancer Therapy-Lymphoma total score, while patients were on the study (data not shown).

Parsaclisib demonstrated a durable response with a safety profile consistent with PI3K inhibitor treatment in patients with R/R MZL. It is important to note that this is the only study of a PI3K inhibitor in patients with R/R MZL that was designed with a pre-determined induction and maintenance phase dosing schedule. This design was implemented to evaluate the ability of a maintenance phase with lower dosing intensity to address tolerability while maintaining efficacy. Two different maintenance doses and dosing schedules were investigated in the current study. Pharmacokinetic modeling data from the phase 1/2 CITADEL-101 study showed that weekly dosing of parsaclisib (20 mg QW) achieved a plasma concentration in excess of the 90% inhibitory concentration (IC_{90}) for maximal inhibition of the protein kinase B (AKT) pathway for 36 hours, but resulted in a plasma concentration below the half-maximal inhibitory concentration (IC_{50}) for approximately half of the dosing interval based on parsaclisib having a half-life of between 8.6–11.5 hours.¹⁸ Comparatively, similar modeling data showed that a daily dosing of parsaclisib (2.5 mg QD) achieved a plasma concentration in excess of IC_{50} for approximately 90% of a weekly dosing interval, indicating less maximal, but more consistent inhibition of AKT, which was hypothesized to offer better clinical efficacy while reducing the severity and frequency of late-onset AEs during the maintenance phase. Based on the pharmacokinetic modeling data, safety and efficacy data from multiple studies investigating parsaclisib monotherapy in the treatment of B-cell lymphoma,^{18,23,24} and early safety and efficacy data from the current study, continuous 2.5 mg QD dosing was selected as the preferred maintenance dosing regimen for the later part of the study—continuous daily dosing at a lower

dose was expected to potentially allow patients to experience durable responses while minimizing side effects.

Overall results in our study revealed that the rate of some TEAEs, especially diarrhea and colitis, were numerically less frequent in WG compared to DG. However, fewer patients were dosed in the WG and the study was not designed to compare the two maintenance doses. In regard to efficacy, the ORR were similar between the DG (58.3%) and WG (57.1%) in our study of piasalisib monotherapy in R/R MZL. These results may suggest that intermittent/weekly dosing providing regular pauses to PI3K pathway inhibition, compared to continuous daily dosing at similar dosing intensity, may improve certain safety events without reducing efficacy in patients treated with piasalisib. However, further clinical investigation is required in order to make firm conclusions due to study design and limited data from the WG group in the current study. Recently, continuous or intermittent dosing was evaluated with another PI3K inhibitor, zandelisib in a phase 1b study of patients with R/R B-cell malignancies.²²

The manageable benefit/risk profile of piasalisib suggests that it may be an effective therapeutic option for patients with R/R MZL. The efficacy results with piasalisib are generally consistent with other PI3K inhibitors that have been investigated for R/R MZL (duvelisib [ORR, 39%],¹² idelalisib [ORR, 57%],²¹ and umbralisib [ORR, 49%]²⁵). However, several PI3K inhibitors previously approved by the US Food and Drug Administration for FL (duvelisib, idelalisib, umbralisib), MZL (umbralisib), and chronic lymphocytic leukemia/small lymphocytic leukemia (idelalisib) have had indications or marketing authorization withdrawn owing to unfavorable feasibility of confirmatory studies or emerging data suggesting increased toxicity and reduced OS in patients with indolent NHL or chronic lymphocytic leukemia.²⁶⁻³⁰ In addition, the treatment landscape for R/R MZL has also evolved since the conduct of the CITADEL-204

study, with newer-generation BTK inhibitors increasingly used for second-line treatment of advanced MZL.³¹ Zanubrutinib was approved under accelerated approval for the treatment of adult patients with R/R MZL who have received at least one anti-CD20–based regimen. In phase 2 studies, acalabrutinib and zanubrutinib achieved ORR of 52.5% and 68.2%, and 12-month DOR rate of 75.8% and 93.0%, respectively, in patients with R/R MZL.^{8,32}

Given that data indicate AEs attributed to PI3K inhibitors are strongly correlated with chronic exposure, modification and optimization of dosing schedules are required to improve the safety and long-term survival benefit observed with PI3K inhibitors, including piasclisib, in patients with NHL. While piasclisib demonstrated meaningful clinical benefit and an overall manageable safety profile in patients with R/R MZL in the current study, a new study will be required to further test the hypothesis that reduction of certain side effects such as diarrhea and colitis could be achieved with a QW maintenance dosing schedule with minimal impact on efficacy. Owing to feasibility of conducting confirmatory phase 3 trials and the evolving treatment landscape, a business decision was made by the sponsor and no additional studies are planned with piasclisib monotherapy in MZL.

Acknowledgments

The authors wish to thank the patients, their families, and the site personnel who participated in this study. This study was sponsored by Incyte Corporation (Wilmington, DE, USA). Medical writing assistance was provided by Rachel Shparberg, PhD (Envision Pharma Group, Philadelphia, PA, USA), and funded by Incyte Corporation.

Authorship

Contribution: All authors contributed to the acquisition, analysis, and interpretation of data, as well as to the drafting and critical review of the manuscript, and provided approval of the final version to be published. TJP, PJ (Johnson), FZ, ER, WZ, and PJ (Jiang) directly accessed and verified the underlying data reported in the manuscript.

Conflict-of-interest disclosure: T.J.P. reports consultancy: AbbVie, Bayer, Beigene, Bristol Myers Squibb, Cardinal Health, Incyte Corporation, Karyopharm, and Seattle Genetics; travel, accommodations, or expenses: Incyte Corporation; and research funding: AstraZeneca and Pharmacyclics. A.A. reports consultancy: Gilead Sciences, Pfizer, and Takeda; honoraria: Janssen; and research funding: Bristol Myers Squibb. R.G. reports consultancy: Gilead Sciences, Medison, Novartis, and Takeda; and honoraria: JC Health CARE and Roche. P.C. reports consultancy: AbbVie, Amgen, Celgene, Daiichi Sankyo, F. Hoffman-La Roche Ltd, Gilead Sciences, Incyte Corporation, Janssen, Kyowa Kirin, Kite, Novartis, Sanofi, Servier, and Takeda; honoraria: AbbVie, Amgen, Celgene, Daiichi Sankyo, F. Hoffman-La Roche Ltd, Gilead Sciences, Janssen, Kyowa Kirin, Kite, Novartis, Sanofi, Servier, and Takeda; other: travel, accommodations, expenses (paid by any for-profit health care company): AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead Sciences, Novartis, and Takeda. A.M. reports consultancy: AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead, Incyte Corporation, Kyowa Kirin, MorphoSys/Incyte Corporation, Novartis, Pharmacyclics, Seattle Genetics, and TG Therapeutics; research funding: Affimed, Celgene/Bristol Myers Squibb, Forty Seven Inc./Gilead, I-MAB, Incyte Corporation, Innate Pharmaceuticals, Juno Pharmaceuticals/Bristol Myers Squibb, Kite/Gilead, Merck, Roche-Genentech, Seattle Genetics, Takeda, and TG

Therapeutics; speakers' bureau: AstraZeneca, Bristol Myers Squibb, Gilead, Kyowa Kirin, Incyte Corporation, MorphoSys/Incyte, Pharmacyclics, Seattle Genetics, and BeiGene. I.S.L. reports consultancy: Janssen Scientific, Seattle Genetics, and Verastem Oncology; honoraria: Janssen Biotech and Verastem Oncology; other: travel, accommodations, expenses (paid by any for-profit health care company): Janssen and Seattle Genetics; patents and royalties: Stanford University; research funding: NCI. P.L.Z. reports consultancy: Bristol Myers Squibb, Celgene, Celltrion, EUSA Pharma, Gilead Sciences, Immune Design, Janssen, MSD, Portola, Roche, Sandoz, Sanofi, and Verastem Oncology; honoraria: AbbVie, ADC Therapeutics, Bristol Myers Squibb, EUSA Pharma, Gilead Sciences, Incyte Corporation, Janssen, Kyowa Kirin, Merck, Roche, Takeda, TG Therapeutics, and Verastem Oncology; membership on an entity's Board of Directors or advisory committees: AbbVie, ADC Therapeutics, Bristol Myers Squibb, Celgene, Celltrion, EUSA Pharma, Gilead Sciences, Immune Design, Incyte Corporation, Janssen, Kyowa Kirin, Merck, MSD, Portola, Roche, Sandoz, Sanofi, Takeda, and Verastem Oncology; research funding: Portola; speakers' bureau: AbbVie, ADC Therapeutics, Bristol Myers Squibb, Celgene, Celltrion, EUSA Pharma, Gilead Sciences, Immune Design, Incyte Corporation, Janssen, Kyowa Kirin, Merck, MSD, Portola, Roche, Sandoz, Takeda, TG Therapeutics, and Verastem Oncology. C.T. reports consultancy: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Collectis, Kite Pharma/Gilead Sciences, Novartis, and Roche; honoraria: AbbVie, Amgen, Bayer, Celgene, Collectis, Incyte Corporation, Kite Pharma/Gilead Sciences, Novartis, and Roche; membership on an entity's Board of Directors or advisory committees: AbbVie, Amgen, Celgene, Collectis, Kite Pharma/Gilead Sciences, Novartis, and Roche; other: travel, accommodations, expenses (paid by any for-profit health care company): AbbVie, Amgen, Bristol Myers Squibb, Celgene, Collectis Kite Pharma/Gilead Sciences, Novartis, and Roche; research funding: Hospira and

Roche; and speakers' bureau: Cellectis. W.J. reports consultancy: Acerta, AstraZeneca, BeiGene, Epizyme, European Medicines Agency, Janssen China R&D, and Sandoz-Novartis; research funding: Acerta, Affimed, Bayer, BeiGene, Celgene, Gilead Sciences, MEI Pharma, Nordic Nanovector, Janssen China R&D, Merck, MorphyoSys, Pharmacyclics, Roche, Servier, Takeda, and TG Therapeutics; and former employment: Jagiellonian University, Kraków, Poland. F.Z. reports employment and stock ownership: Incyte Corporation. E.R. reports employment and stock ownership: Incyte Corporation. W.Z. reports former employment and stock ownership: Incyte Corporation. P.J. reports former employment and stock ownership: Incyte Corporation. P.J. reports consultancy: Epizyme, Janssen, MorphoSys, OncoImmune Inc, and Takeda; honoraria: Bristol Myers Squibb, Celgene, Genmab, Incyte Corporation, Kite Pharma, Kymera, Novartis, and OncoImmune Inc; and research funding: Epizyme. C.P. and M.T. report no relevant financial relationships to disclose.

References

1. Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. *Expert Rev Anticancer Ther.* 2015;15(5):531-544.
2. Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2020;31(1):17-29.
3. National Comprehensive Cancer Network Guidelines. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology™ B-Cell Lymphomas Version 4.2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed April 12, 2023.

4. Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. *Blood*. 2017;129(16):2224-2232.
5. Celgene Corporation. REVLIMID (lenalidomide) capsules for oral use [prescribing information]. 2022; https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021880s0651bl.pdf. Accessed November 24, 2022.
6. Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. *J Clin Oncol*. 2019;37(14):1188-1199.
7. BeiGene USA, Inc. BRUKINSA (zanubrutinib) capsules, for oral use [prescribing information]. 2022; <https://www.brukinsa.com/prescribing-information.pdf>. Accessed November 24, 2022.
8. Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma. *Clin Cancer Res*. 2021;27(23):6323-6332.
9. AbbVie Inc. Update on IMBRUVICA® (ibrutinib) U.S. accelerated approvals for mantle cell lymphoma and marginal zone lymphoma indications [press release]. 2023; <https://news.abbvie.com/news/press-releases/update-on-imbruvica-ibrutinib-us-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications.htm>. Accessed June 19, 2023.

10. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. *Blood*. 2006;108(5):1668-1676.
11. Phillips TJ, Michot JM, Ribrag V. Can next-generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma? *Clin Lymphoma Myeloma Leuk*. 2021;21(1):8-20.e23.
12. Flinn IW, Miller CB, Ardeschna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. *J Clin Oncol*. 2019;37(11):912-922.
13. Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. *Am J Hematol*. 2020;95(4):362-371.
14. Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3K δ /CK1 ϵ inhibitor in patients with relapsed or refractory indolent lymphoma. *J Clin Oncol*. 2021;39(15):1609-1618.
15. Panayiotidis P, Follows GA, Mollica L, et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. *Blood Adv*. 2021;5(3):823-828.
16. Yue EW, Li YL, Douty B, et al. INCB050465 (parsaclisib), a novel next-generation inhibitor of phosphoinositide 3-kinase delta (PI3K δ). *ACS Med Chem Lett*. 2019;10(11):1554-1560.

17. Shin N, Stubbs M, Koblisch H, et al. Parsaclisib is a next-generation phosphoinositide 3-kinase δ inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy. *J Pharmacol Exp Ther.* 2020;374(1):211-222.
18. Forero-Torres A, Ramchandren R, Yacoub A, et al. Parsaclisib, a potent and highly selective PI3K δ inhibitor, in patients with relapsed or refractory B-cell malignancies. *Blood.* 2019;133(16):1742-1752.
19. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol.* 2014;32(27):3059-3068.
20. Lynch RC, Avigdor A, McKinney MS, et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma: primary analysis from a phase 2 study (CITADEL-203). *Blood.* 2021;138 (Supplement 1): 813.
21. Gopal AK, Kahl BS, de Vos S, et al. PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med.* 2014;370(11):1008-1018.
22. Pagel JM, Soumerai JD, Reddy N, et al. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. *Lancet Oncol.* 2022;23(8):1021-1030.
23. Trněný M, Avigdor A, McKinney MS, et al. Parsaclisib, a PI3K δ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study. *eClinicalMedicine.* 2023;63.

24. Zinzani PL, Trněný M, Ribrag V, et al. Parsaclisib, a PI3K δ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study. *eClinicalMedicine*. 2023;62.
25. Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open label, registration directed phase II study [abstract]. *J Clin Oncol*. 2019;37(15 Suppl):7506.
26. Secura Bio, Inc. Secura Bio announces Copiktra[®] (duvelisib) strategic focus on T-cell lymphoma and voluntary U.S. withdrawal of the relapsed or refractory follicular lymphoma indication [press release]. 2021; <https://www.prnewswire.com/news-releases/secura-bio-announces-copiktra-duvelisib-strategic-focus-on-t-cell-lymphoma-and-voluntary-us-withdrawal-of-the-relapsed-or-refractory-follicular-lymphoma-indication-301436834.html>. Accessed November 24, 2022.
27. Gilead Sciences Inc. Gilead statement on Zydelig[®] U.S. indication for follicular lymphoma and small lymphocytic leukemia [press release]. 2022; <https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-zydelig-us-indication-for-follicular-lymphoma-and-small-lymphocytic-leukemia>. Accessed November 24, 2022.
28. TG Therapeutics Inc. TG Therapeutics announces voluntary withdrawal of the BLA/sNDA for U2 to treat patients with CLL and SLL [press release]. 2022; <https://www.globenewswire.com/news-release/2022/04/15/2423276/8790/en/TG-Therapeutics-Announces-Voluntary-Withdrawal-of-the-BLA-sNDA-for-U2-to-Treat-Patients-with-CLL-and-SLL.html>. Accessed November 24, 2022.

29. US Food and Drug Administration. Phosphatidylinositol 3-kinase (PI3K) inhibitors in hematologic malignancies. ODAC briefing document. 2022.

<https://www.fda.gov/media/157762/download>. Accessed June 16, 2022.

30. NC Richardson, Y Kasamon, R Pazdur, N Gormley. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. *The Lancet Oncology*. 2022;23(5):563-566.

31. National Comprehensive Cancer Network Guidelines. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology™ B-Cell Lymphomas Version 5.2023.

https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed September 12, 2023.

32. Strati P, Coleman M, Champion R, et al. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. *Br J Haematol*. 2022;199(1):76-85.

TABLES

Table 1. Baseline demographics and clinical characteristics (cohort 2)

Characteristic	Weekly dosing group (n = 28)	Daily dosing group (n = 72)	All treated patients (N = 100)
Age, median (range), years	67.0 (52–86)	72.0 (35–95)	71.0 (35–95)
≥65 years, n (%)	20 (71.4)	52 (72.2)	72 (72.0)
Male, n (%)	12 (42.9)	41 (56.9)	53 (53.0)
Race, n (%)			
White	23 (82.1)	60 (83.3)	83 (83.0)
Other*	5 (17.9)	12 (16.7)	17 (17.0)
ECOG PS score, n (%)			
0	15 (53.6)	46 (63.9)	61 (61.0)
1	11 (39.3)	23 (31.9)	34 (34.0)
2	2 (7.1)	3 (4.2)	5 (5.0)
MZL disease subtype, n (%)			
Nodal	6 (21.4)	25 (34.7)	31 (31.0)
Extranodal	11 (39.3)	23 (31.9)	34 (34.0)
Splenic	11 (39.3)	24 (33.3)	35 (35.0)
Ann Arbor staging, n (%)			
I	1 (3.6)	6 (8.3)	7 (7.0)
II	3 (10.7)	4 (5.6)	7 (7.0)
III	1 (3.6)	7 (9.7)	8 (8.0)
IV	27 (78.6)	52 (72.2)	74 (74.0)
Unknown/missing[†]	1 (3.6)	3 (4.2)	4 (4.0)

Time since diagnosis, median (range), years	4.7 (0.3–20.1)	4.4 (0.1–19.8)	4.6 (0.1–20.1)
Number of prior treatments, median (range)	1.0 (1–8)	2.0 (1–5)	2.0 (1–8)
Prior therapies, n (%)			
Anti-CD20 mAb	28 (100)	72 (100)	100 (100)
Chemotherapy	19 (67.9)	53 (73.6)	72 (72.0)
Surgery/surgical procedures	8 (28.6)	11 (15.3)	19 (19.0)
Radiation	4 (14.3)	7 (9.7)	11 (11.0)
HSCT	1 (3.6)	3 (4.2)	4 (4.0)
Status to most recent prior therapy, n (%)			
Relapsed	13 (46.4)	33 (45.8)	46 (46.0)
Refractory	14 (50.0)	35 (48.6)	49 (49.0)
Unknown	1 (3.6)	4 (5.6)	5 (5.0)

ECOG PS, Eastern Cooperative Oncology Group performance status; HSCT, hematopoietic stem cell transplantation; mAb, monoclonal antibody; MZL, marginal zone lymphoma.

*Includes one Black patient and one Asian patient enrolled in the daily dosing group. †Ann Arbor staging was indicated as unknown for three patients and not applicable for one patient at baseline.

Table 2. Best overall response, and ORR and CRR among patients receiving piasclisib by IRC review (cohort 2)

Response	Weekly dosing group (n = 28)	Daily dosing group (n = 72)	All treated patients (N = 100)
Best overall response, n (%)			
Complete response	3 (10.7)	3 (4.2)	6 (6.0)
Partial response	13 (46.4)	39 (54.2)	52 (52.0)
Stable disease	7 (25.0)	22 (30.6)	29 (29.0)
Progressive disease	2 (7.1)	0	2 (2.0)
Not evaluable/assessed*	3 (10.7)	8 (11.1)	11 (11.0)
ORR, % (95% CI)	57.1 (37.2–75.5)	58.3 (46.1–69.8)	58.0 (47.7–67.8)
CRR, % (95% CI)	10.7 (2.3–28.2)	4.2 (0.9–11.7)	6.0 (2.2–12.6)

CI, confidence interval; CRR, complete response rate; IRC, independent review committee; ORR, objective response rate.

*2 patients in WG and 2 patients in DG (4 total overall) were not evaluable owing to no disease per IRC in 3 patients, and insufficient anatomical coverage per IRC in 1 patient; 1 patient in WG and 6 patients in DG (7 total overall) did not have post-baseline measurement and could not be assessed.

Table 3. Most common any-grade TEAEs (occurring in $\geq 10\%$ of patients in the total population) and grade ≥ 3 TEAEs among patients receiving parsacalisib (cohort 2)

Preferred term (MedDRA), n (%)	Weekly dosing group (n = 28)		Daily dosing group (n = 72)		All treated patients (N = 100)	
	Any		Any		Any	
	grade	Grade ≥ 3	grade	Grade ≥ 3	grade	Grade ≥ 3
Any TEAE	26 (92.9)	11 (39.3)	70 (97.2)	52 (72.2)	96 (96.0)	63 (63.0)
Diarrhea*	9 (32.1)	1 (3.6)	38 (52.8)	11 (15.3)	47 (47.0)	12 (12.0)
Cough	4 (14.3)	0	19 (26.4)	1 (1.4)	23 (23.0)	1 (1.0)
Rash	5 (17.9)	0	13 (18.1)	2 (2.8)	18 (18.0)	2 (2.0)
Anemia	3 (10.7)	0	12 (16.7)	6 (8.3)	15 (15.0)	6 (6.0)
Nausea	3 (10.7)	0	12 (16.7)	0	15 (15.0)	0
Pruritus	5 (17.9)	0	10 (13.9)	0	15 (15.0)	0
Pyrexia	4 (14.3)	0	11 (15.3)	1 (1.4)	15 (15.0)	1 (1.0)
Fatigue	3 (10.7)	0	11 (15.3)	1 (1.4)	14 (14.0)	1 (1.0)
Constipation	2 (7.1)	0	11 (15.3)	0	13 (13.0)	0
Decreased appetite	2 (7.1)	0	11 (15.3)	0	13 (13.0)	0
Headache	3 (10.7)	0	10 (13.9)	0	13 (13.0)	0
Neutropenia	3 (10.7)	1 (3.6)	10 (13.9)	8 (11.1)	13 (13.0)	9 (9.0)
URTI	0	0	13 (18.1)	2 (2.8)	13 (13.0)	2 (2.0)
Abdominal pain	1 (3.6)	0	11 (15.3)	3 (4.2)	12 (12.0)	3 (3.0)
Arthralgia	4 (14.3)	0	8 (11.1)	2 (2.8)	10 (10.0)	2 (2.0)
Colitis	0	0	10 (13.9)	7 (9.7)	10 (10.0)	7 (7.0)
Dizziness	2 (7.1)	0	8 (11.1)	0	10 (10.0)	0

Peripheral edema	2 (7.1)	0	8 (11.1)	0	10 (10.0)	0
Pneumonia	2 (7.1)	2 (7.1)	8 (11.1)	7 (9.7)	10 (10.0)	9 (9.0)
UTI	3 (10.7)	0	7 (9.7)	1 (1.4)	10 (10.0)	1 (1.0)

MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event; URTI, upper respiratory tract infection; UTI, urinary tract infection.

*Time to onset of diarrhea (months): weekly dosing 3.6 (range, 1.05–10.8); daily dosing 2.6 (range, 0.03–23.85); all treated patients 2.7 (range, 0.03–23.85).

Table 4. TEAEs of special interest (cohort 2)

Preferred term (MedDRA), n (%)	Weekly dosing group (n = 28)		Daily dosing group (n = 72)		All treated patients (N = 100)	
	Any		Any		Any	
	grade	Grade ≥3	grade	Grade ≥3	grade	Grade ≥3
Colitis	0	0	10 (13.9)	7 (9.7)	10 (10.0)	7 (7.0)
Cytomegalovirus infection	0	0	2 (2.8)	1 (1.4)	2 (2.0)	1 (1.0)
Diarrhea	9 (32.1)	1 (3.6)	38 (52.8)	11 (15.3)	47 (47.0)	12 (1.0)
Febrile neutropenia	1 (3.6)	1 (3.6)	4 (5.6)	4 (5.6)	5 (5.0)	5 (5.0)
Herpes simplex	0	0	1 (1.4)	0	1 (1.0)	0
Pneumonia	2 (7.1)	2 (7.1)	8 (11.1)	7 (9.7)	10 (10.0)	9 (9.0)
Pneumonitis	0	0	2 (2.8)	1 (1.4)	2 (2.0)	1 (1.0)
Rash	5 (17.9)	0	13 (18.1)	2 (2.8)	18 (18.0)	2 (2.0)

MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event.

Figure 1. Best percentage change from baseline in either target lesions for patients with measurable disease at baseline and at least 1 valid postbaseline measurement (blue bars, n = 71) or enlarged portion of spleen for patients with splenomegaly only at baseline and at least 1 valid postbaseline measurement of spleen (green bars, n = 10) by independent review committee (cohort 2 weekly and daily dosing groups).

Figure 2. (A) Cumulative time to response curves, and (B) Kaplan-Meier estimates of duration of response (DOR), (C) progression-free survival (PFS), and (D) overall survival (OS) in the daily dosing group (blue) and all treated patients (green) (cohort 2). All response assessments were by independent review committee.




Figure 1

Figure 2

